Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

All nine patients showed a “successful anti-cancer immune response” after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.

Lainie Jones has Li-Fraumeni syndrome, which makes her predisposed to having cancer. She's undergoing treatment for ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Scientists led by Prof. Liu Jing from the Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences ...

Mitochondria, the powerhouse of the cell, plays a crucial role in reshaping the metabolic reprogramming of cancer cells and TILs.

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...

The immune system plays a key role in detecting and destroying cancer cells. Cancer immunotherapy works by programming immune cells to recognize and eliminate cancer cells.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...